版权说明 操作指南
首页 > 成果 > 详情

[Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Chen, Y Q;Zhang, Y D;Yan, H;Qin, H Y;Huang, Z;...
作者机构:
[Zhang, Y D; Chen, Y Q; Yan, H; Huang, Z; Qin, H Y; Zhang, X] Department of Medical Oncology, Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China
[Xiang, S Q] Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou 416000, China
[Hu, X Q] Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410078, China
[Wu, F] Department of Pathology, Immuno-Oncology Laboratory, School of Basic Medicine, Central South University, Changsha 410017, China
[Zhang, Y C; Zeng, L; Yang, N] Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha 410013, China
语种:
中文
期刊:
中华医学杂志
ISSN:
0376-2491
年:
2024
卷:
104
期:
4
页码:
282-289
机构署名:
本校为第一机构
院系归属:
医学院
摘要:
Objective: To compare the efficacy and safety of domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer. Methods: A retrospective analysis was conducted on the data of 1 241 patients with driver gene-negative, unresectable stage ⅢB to Ⅳ non-small cell lung cancer who were treated at the Hunan Cancer Hospital from January 1, 2017 to October 1, 2022. All patients received monotherapy or combination therapy with domestic immune checkpoint inhibitors or pembrolizumab. A...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com